A second three-month Phase 3 efficacy study of AR-15512 for the treatment of dry eye disease
Latest Information Update: 15 Mar 2023
At a glance
- Drugs Acoltremon (Primary)
- Indications Dry eyes
- Focus Therapeutic Use
- 04 Nov 2021 According to an Aerie Pharmaceuticals media release, the company expect to initiate this study in the first half of 2022 after the end of Phase 2 meeting with the U.S. Food and Drug Administration (FDA) in the first quarter of 2022.
- 21 Sep 2021 New trial record